Prof Rupert Bauersachs (Clinic Darmstadt, Darmstadt, DE) discusses the results from the VOYAGER PAD trial. The aim of the trial was to evaluate rivaroxaban/aspirin compared with placebo/aspirin among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization.
- What is the VOYAGER PAD Trial and what does it aim to address?
- What was the study design, patient population and endpoints?
- What are the main findings to date?
- What conclusions can be made and what are the implications on practice?
- What are the next steps?
Recorded remotely from Darmstadt, 2021.
Editor: Mirjam Boros